Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics European Union - English - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human - vaccines - active immunisation against h5n1 subtype of influenza a virus.; this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain.; prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics European Union - English - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain a/viet nam/1194/2004 (h5n1) - influenza, human, immunization, disease outbreaks - vaccines, - active immunisation against h5n1 subtype of influenza a virus., this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain., prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.,

Herceptin SC New Zealand - English - Medsafe (Medicines Safety Authority)

herceptin sc

roche products (nz) ltd - trastuzumab 120 mg/ml - solution for injection - 600 mg/5ml - active: trastuzumab 120 mg/ml excipient: histidine histidine hydrochloride monohydrate hyaluronidase methionine polysorbate 20 trehalose dihydrate water for injection - herceptin sc is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: a) as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; or b) in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or c) in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.

Mabthera SC New Zealand - English - Medsafe (Medicines Safety Authority)

mabthera sc

roche products (nz) ltd - rituximab 1600mg;   - solution for injection - 1600mg/13.4ml - active: rituximab 1600mg   excipient: histidine histidine hydrochloride methionine polysorbate 80 trehalose dihydrate vorhyaluronidase alfa water for injection - mabthera sc 1600 mg in combination with chemotherapy is indicated for the treatment of patients with chronic lymphocytic leukaemia

MABTHERA SC rituximab (rch) 1600 mg/13.4 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

mabthera sc rituximab (rch) 1600 mg/13.4 ml solution for injection vial

roche products pty ltd - rituximab, quantity: 1600 mg - injection - excipient ingredients: vorhyaluronidase alfa; histidine; histidine hydrochloride; trehalose dihydrate; methionine; polysorbate 80; water for injections - mabthera sc 1600 mg is indicated for the treatment of patients with cd20 positive chronic lymphocytic leukaemia (cll) in combination with chemotherapy.

MABTHERA SC rituximab (rch) 1400 mg/11.7 mL solution for injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

mabthera sc rituximab (rch) 1400 mg/11.7 ml solution for injection vial

roche products pty ltd - rituximab, quantity: 1400 mg - injection - excipient ingredients: vorhyaluronidase alfa; histidine; histidine hydrochloride; trehalose dihydrate; methionine; polysorbate 80; water for injections - mabthera sc is indicated for treatment of patients with: - cd20 positive, previously untreated, stage iii/iv follicular, b-cell non-hodgkin's lymphoma, - cd20 positive, relapsed or refractory low grade or follicular, b-cell non-hodgkin's lymphoma, - cd 20 positive, diffuse large b-cell non-hodgkin's lymphoma, in combination with chemotherapy.

SC HEALTH INSTANT HAND SANITIZER- alcohol gel United States - English - NLM (National Library of Medicine)

sc health instant hand sanitizer- alcohol gel

sc health spv, llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - for hand sanitizing to decrease bacteria on the skin.

SC HEALTH ANTIBACTERIAL WIPES- benzalkonium chloride cloth United States - English - NLM (National Library of Medicine)

sc health antibacterial wipes- benzalkonium chloride cloth

sc health spv, llc - benzalkonium chloride 0.1%, antibacterial - for hand sanitizing to decrease bacterial on the skin.  recommended for repeat use

SC HEALTH HAND SANITIZER GEL SINGLE USE PACKETS- alcohol gel United States - English - NLM (National Library of Medicine)

sc health hand sanitizer gel single use packets- alcohol gel

sc health spv, llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - for hand sanitizing to decrease bacterial on the skin. 

SC HEALTH HAND SANITIZER- alcohol spray, metered United States - English - NLM (National Library of Medicine)

sc health hand sanitizer- alcohol spray, metered

sc health spv, llc - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - for hand-washing to decrease bacteria on the skin, only when water is not available.